John Cox insider trades

Open-market stock purchases and sales by John Cox, CEO & President at Dyne Therapeutics, Inc, from SEC Form 4 filings since Oct 28, 2010.

Track record: 33% of 3 scored buys are up 5% or more since purchase, averaging +5%.

Recent trades

DateStockTradeValue
Sep 8, 2026DYN Dyne Therapeutics, IncSold$107K
Aug 13, 2026DYN Dyne Therapeutics, IncSold$131K
Jun 16, 2026DYN Dyne Therapeutics, IncSold$49.2K
May 13, 2026DYN Dyne Therapeutics, IncSold$60.8K
Mar 5, 2026DYN Dyne Therapeutics, IncSold$40.7K
Feb 12, 2026DYN Dyne Therapeutics, IncBought (not open market)—
Feb 12, 2026DYN Dyne Therapeutics, IncBought (not open market)—
Dec 5, 2025DYN Dyne Therapeutics, IncSold$55.2K

Companies traded

  • DYN Dyne Therapeutics, Inc: 3 buys, 9 sales, last Sep 8, 2026
  • SGTX Sigilon Therapeutics, Inc: other filings, last Aug 11, 2023
  • RGEN Repligen Corp: 7 sales, last Mar 24, 2020
  • BIVV Bioverativ Inc: other filings, last Mar 8, 2018
  • BIIB Biogen Inc: 13 sales, last Apr 1, 2016

Get free alerts when John Cox files a new trade →